Blue Horseshoe Stocks: CLTX Recap & More

Celsus Therapeutics Plc. CLTX

The big winner from yesterday’s report turned out to be CLTX. We tagged the stock after catching it on a routine news scan; the company announced an all-stock exchange agreement with Volution Immuno Pharmaceuticals in which CLTX will absorb the company as a wholly-owned subsidiary, and form a new company aimed at developing treatments for a range of rare and orphan autoimmune and inflammatory diseases >> READ PR

Back in February, a bleak annual report led CLTX to fall off of a cliff, tumbling from the $6+ range down to roughly a dollar. Over the next several months, the stock continued to trend downward, culminating in a 52-week low of .40 at the end of May. Since that time, it received a little boost, rising to the .60-range.

That’s where we came upon it yesterday, and it was fortunate that we began paying attention when we did. After dipping to a daily low of .5012, the stock ran into the close, reaching a high of .68; a solid 36% intraday move. The late boost of momentum is carrying over into the premarket today, with CLTX hitting an early high of .99. From our observed low yesterday, that’s a 98% swing.

We’ll look for it to continue to build its base with higher lows, and to potentially crack through resistance into dollar-territory.


Callaway Golf Co. ELY

ELY is contributing to the newsreel this morning, announcing the signing of a highly talented young golfer. Upon taking notice of this, we’ve also seen that ELY has been building a heck of a chart setup over the past few sessions.

The stock has registered higher lows for each of the last four consecutive trading sessions, and is exhibiting a great deal of promise with regard to a number of bullish signals on the chart that we’ve pointed out on the snapshot below. Between that, and it being the peak of golf season, we’ll be paying close attention to ELY.

CARLSBAD, Calif., July 14, 2015 /PRNewswire/ — Today Callaway Golf officially announced that it has reached a Staff Pro agreement with former college golf phenom, Julien Brun. A native of Anitbes, France, Brun turns pro after an unbelievable career at Texas Christian University (TCU), where he was a 3-time First Team All-American and a 3-time Academic All-American.>> FULL PR


EnteroMedics, Inc.  ETRM

Speaking of ripening charts, we’ve got to tag ETRM this morning as a bottom-play that could be in line for a serious rebound. One look at the chart is all it takes to see what we mean.

We’ve got an egregiously oversold RSI, and the stock has fallen to new 52-week lows in the past couple of sessions.  There are also a couple of gaps to fill from 44-.50 and from .83-.96 on a possible retrace, so we’ll be monitoring this play which we feel has breakout potential based on these factors.


Extended Watchlist:
BIOC, CLSN, TBIO, CEL, VLTC, CPXX

Blue Horseshoe Stocks: Potential Bottom-Plays & More

Solaris Power Cells, Inc. SPCL

We’ve got a news play hitting our scanner this morning in SPCL, and as it turns out, the chart is looking ripe for a nice move. As we’ve pointed out on the following snapshot, the stock is trading near a relative bottom, having just registered a new 52-week low just two weeks ago.

Our regular readers are well acquainted with our history of banking excellent gains off a good rebound play. SPCL could be next in line on that front, so we’ll keep a sharp eye on it to start the week.

In addition to trading near a bottom, we’re seeing signs of a very oversold stock with a lot of room to the upside:

PALM SPRINGS, Calif., July 13, 2015 (GLOBE NEWSWIRE) — Solaris Power Cells, Inc. the creators of the Solaris PESATM “Passive Electron Storage Array”™, (the “Company”) (OTCQB:SPCL)  the Board of Directors of Solaris Power Cells today announced the appointment of long-time energy policy leader Robert Foster to lead Solaris Energy Storage Advisory Board, effective July 10th 2015. >> FULL PR


OncoGenex Pharmaceuticals, Inc OGXI

OGXI announced this morning that one of its cancer treatments, currently in Phase III trials has passed rigorous criteria and
that trials for patients with non-small cell lung cancer will proceed as planned. The stock is gapping up in premarket trading, and we’re going to monitor its activity as the session commences.

BOTHELL, Wash. and VANCOUVER, British Columbia, July 13, 2015 /PRNewswire/ — OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per the recommendation of an Independent Data Monitoring Committee>> FULL PR



Frontline, Ltd. FRO

We’ve got a long history with FRO that stretches all the way back to 2012. We tagged FRO in Thursday’s premarket report, after it hit a relative bottom of 2.21 on Wednesday. Our observed low following Thursday’s alert was 2.32, and on Friday we saw as the stock inched up to a high of 2.43. We’re going to be on the lookout for further gains; the stock is gapping up slightly in early trading this morning.

An added element to the story is an opinion article that came across the wires last week pertaining to the perceived undervaluation of FRO. It points to a potential longer-term uptrend in the cards, stating that while this year’s earnings growth is expected to top last year’s by more than 200%, that hasn’t really been reflected in the share price. We suggest our subscribers click the following link and give it a read >> VIEW ARTICLE


Extended Watchlist:
PSDV, GILT, FREE, GRPN, DANG, CLTX, DRYS